Ferrettini C, Pirulli D, Cosseddu D, Marangella M, Petrarulo M, Mazzola G, Vatta S, Amoroso A
Laboratorio Calcolosi Renale, Ospedale Mauriziano Umberto I, Torino, Italy.
J Nephrol. 1998 Mar-Apr;11 Suppl 1:18-22.
Specimens were collected from 22 Italian patients with primary hyperoxaluria type 1 (PH1). Ten of them had already been analyzed by molecular biology. To clarify the molecular characteristics of the AGXT gene disease responsible for PH1, DNA samples were examined for known mutations by hybridisation of PCR products with Sequence Specific Oligonucleotides (PCR-SSO). We planned to identify new mutations of the AGXT gene by heteroduplex analysis followed by direct sequencing. We had already standardized a) the conditions for the amplification of the 11 exons of AGXT, b) the PCR-SSO technique and c) the heteroduplex analysis of amplified products. Preliminary results demonstrated that the AGXT mutations described in previous studies were found only in 40% of the examined Italian patients with PH1. The remaining 60% of mutations should be characterised in future studies.
从22名患有1型原发性高草酸尿症(PH1)的意大利患者身上采集了样本。其中10名患者已经通过分子生物学进行了分析。为了阐明导致PH1的AGXT基因疾病的分子特征,通过将PCR产物与序列特异性寡核苷酸杂交(PCR-SSO)来检测DNA样本中的已知突变。我们计划通过异源双链分析随后直接测序来鉴定AGXT基因的新突变。我们已经标准化了:a)AGXT 11个外显子的扩增条件,b)PCR-SSO技术,以及c)扩增产物的异源双链分析。初步结果表明,先前研究中描述的AGXT突变仅在40%的接受检测的意大利PH1患者中被发现。其余60%的突变应在未来的研究中进行表征。